title: Unfractioned heparin for treatment of sepsis: A randomized clinical trial (The HETRASE Study).
abstract: OBJECTIVE
  The primary aims of this study were to determine the effects of heparin on length of stay and change from baseline multiple organ dysfunction (MOD) score. Secondary objectives were to estimate the effects of heparin on 28-day all-cause mortality, and to determine the possible effect modification on 28-day all-cause mortality, in subgroups defined by site of infection and baseline values of Acute Physiology and Chronic Health Evaluation II score, MOD score, and d-dimer.
  
  
  METHODS
  Randomized, double-masked, placebo-controlled, single-center clinical trial, testing low dose continuous infusion of unfractioned heparin (UFH) as complementary treatment for sepsis.
  
  
  METHODS
  Five hundred fifty bed University Hospital and referral center in Medellín, Columbia.
  
  
  METHODS
  Three hundred nineteen patients admitted at the emergency room with signs indicative of sepsis.
  
  
  METHODS
  Patients were randomly assigned to receive placebo or UFH (500 units/hour for 7 days).
  
  
  RESULTS
  The median length of stay in patients discharged alive in the placebo group was 12.5 days (interquartile range = 8-20), and 12 days (interquartile range = 8-19.5) in the heparin group (p = 0.976). The MOD score improved equally in the two treatments arms with an average decline of 0.13 and 0.11 per day for the placebo and heparin groups (p = 0.240), respectively. The overall 28-day mortality was 16% in the placebo group and 14% in the heparin group (p = 0.652). Subgroup analyses did not show any statistically significant reduction in 28-day mortality with UFH. There was only one serious adverse event on a patient who received heparin but it was fully resolved without complications.
  
  
  CONCLUSIONS
  Our findings suggested that UFH may be a feasible and safe intervention in sepsis. However, this study was not able to demonstrate a beneficial effect on the chosen primary outcomes or in the 28-day mortality rate.
authors.affiliation: Department of Internal Medicine, School of Medicine, Universidad de Antioquia, Medellín, Colombia. fjaimes@udea.edu.co
authors.forename: Fabián
authors.initials: F
authors.lastname: Jaimes
authors.forename: Gisela
authors.initials: G
authors.lastname: De La Rosa
authors.forename: Carlos
authors.initials: C
authors.lastname: Morales
authors.forename: Fernando
authors.initials: F
authors.lastname: Fortich
authors.forename: Clara
authors.initials: C
authors.lastname: Arango
authors.forename: Daniel
authors.initials: D
authors.lastname: Aguirre
authors.forename: Alvaro
authors.initials: A
authors.lastname: Muñoz
mesh_terms: D000328:Adult; D000368:Aged; D000925:Anticoagulants / Q000008:administration & dosage*; D004311:Double-Blind Method; D005260:Female; D006493:Heparin / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D008875:Middle Aged; D018805:Sepsis / Q000188:drug therapy* / Q000401:mortality
chemical_list: D000925:Anticoagulants; D006493:Heparin